CriticalSelective irreversible MAO-B inhibitor×Serotonin antagonist and reuptake inhibitor (SARI) antidepressant
Updated · Methodology
Mechanism
Trazodone inhibits serotonin reuptake at the presynaptic level and blocks 5-HT2A serotonin receptors at the postsynaptic level (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label classes it as a selective serotonin reuptake inhibitor (trazodone label, US Food and Drug Administration, FDA). Selegiline irreversibly inhibits monoamine oxidase type B (MAO-B) and belongs to the MAO inhibitors. At the recommended dose of up to 10 mg a day it acts selectively, and at higher doses it may lose its selectivity (selegiline SmPC, AEMPS). After a single 10 mg dose, platelet MAO-B activity returns to normal in about 2 weeks (selegiline SmPC, AEMPS). MAO inhibitors impair serotonin metabolism and, together with serotonergic drugs such as trazodone, raise the risk of serotonin syndrome (trazodone FDA label).
Symptoms
Serotonin syndrome can be life-threatening (trazodone label, US Food and Drug Administration, FDA). It presents with mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, high temperature), neuromuscular signs (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, nausea, vomiting or diarrhoea (trazodone FDA label). Post-marketing reports describe cases of serotonin syndrome, some of them fatal, in people taking selegiline with antidepressants. Serotonin syndrome with hyperpyrexia has also been reported when selegiline was combined with triazolopyridine antidepressants, the group trazodone belongs to (selegiline FDA label). The Spanish trazodone summary of product characteristics (SmPC) describes serotonin syndrome and neuroleptic malignant syndrome with monoamine oxidase inhibitors and other serotonergic drugs (trazodone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The US trazodone label contraindicates the combination. Trazodone is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping them, with no exception for the MAOI dose or indication (trazodone label, US Food and Drug Administration, FDA), and selegiline is an MAO-B inhibitor according to its own summary of product characteristics (selegiline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish documents are less strict: the trazodone SmPC does not recommend combining trazodone with MAOIs, although it notes that some doctors prescribe them together (trazodone SmPC, AEMPS), and the selegiline SmPC does not name trazodone (selegiline SmPC, AEMPS). The US label of selegiline orally disintegrating tablets says to avoid combining selegiline with any antidepressant (selegiline FDA label). Start trazodone no earlier than 14 days after stopping selegiline (trazodone and selegiline FDA labels); the Spanish trazodone SmPC also does not recommend starting it during the first 2 weeks after an MAOI (trazodone SmPC, AEMPS). Stop trazodone before starting an MAOI (trazodone FDA label); the Spanish trazodone SmPC does not recommend giving an MAOI one week after stopping trazodone (trazodone SmPC, AEMPS). If signs of serotonin syndrome appear, stop trazodone and other serotonergic drugs at once and start supportive symptomatic treatment (trazodone FDA label; trazodone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Zelapar (selegiline hydrochloride) prescribing information (2021)– FDA label, Bausch Health US, LLC, DailyMed setid 380d7717-2a79-42f3-a712-efe5e7696ba0, revised 06/2021, sections 4, 5.1 and 7.1
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- AEMPS: Ficha técnica: Trazodona, Deprax 100 mg (nº registro 78762), sección 4.5 (2023)– AEMPS, CIMA, nº registro 78762 (Deprax 100 mg comprimidos recubiertos con película, Angelini Pharma España), revisión 11/2023, secciones 4.4, 4.5 y 5.1